List of Tivicay Pd drug patents

Tivicay Pd is owned by Viiv Hlthcare.

Tivicay Pd contains Dolutegravir Sodium.

Tivicay Pd has a total of 2 drug patents out of which 0 drug patents have expired.

Tivicay Pd was authorised for market use on 12 June, 2020.

Tivicay Pd is available in tablet, for suspension;oral dosage forms.

The generics of Tivicay Pd are possible to be released after 08 December, 2029.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8129385 VIIV HLTHCARE Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness
Oct, 2027

(4 years from now)

US9242986 VIIV HLTHCARE Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
Dec, 2029

(6 years from now)

Drugs and Companies using DOLUTEGRAVIR SODIUM ingredient

Market Authorisation Date: 12 June, 2020

Treatment: NA

Dosage: TABLET, FOR SUSPENSION;ORAL

How can I launch a generic of TIVICAY PD before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in